NEJM corrects its study on rofecoxibBMJ 2006; 333 doi: https://doi.org/10.1136/bmj.333.7557.12-b (Published 29 June 2006) Cite this as: BMJ 2006;333:12
- Susan Mayor
An increase in cardiovascular events associated with the cyclooxygenase-2 inhibitor rofecoxib (Vioxx) occurred much earlier in the course of treatment than the original study reporting the problem had indicated, says a correction published online in the New England Journal of Medicine on 26 June (http://content.nejm.org/, doi: 10.1056/NEJMx06).
The correction to the study of …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial